Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280576 | 0.73 | NOS3 (0.34) | KMT2AMAPT | |
| SCHEMBL13996911 | 0.66 | CRHBP (0.52) | KMT2AMAPT | |
| SCHEMBL19203178 | 0.64 | ALDH1A1 (0.40) | KMT2AMAPT | |
| SCHEMBL24158149 | 0.64 | ALDH1A1 (0.34) | MAPT | |
| SCHEMBL19216519 | 0.64 | MAPT (0.41) | HTTKMT2AMAPT | |
| SCHEMBL21164945 | 0.63 | RXFP1 (0.37) | HTTKMT2AMAPT | |
| Hydrazine SCHEMBL5026845 | 0.63 | CDK2 (0.33) | HTTKMT2ACCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL18317014 | 0.63 | ALDH1A1 (0.42) | KMT2ACDK2MAPT | |
| SCHEMBL14490774 | 0.63 | CDK2 (0.42) | HTTKMT2ACCNA2CDK2CCNA1 | |
| SCHEMBL11192342 | 0.63 | CDK2 (0.41) | KMT2ACCNA2CDK2CCNA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | HTT 2214/4885KMT2A 2891/4885CCNA2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.